WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “Irish Takeover Rules”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the “Proxy Statement”) and that Mural has commenced mailing the Pr ...

Group 1 - XOMA Royalty's shares have increased by 14.8% in the past four weeks, closing at $37.59, with a mean price target of $69.67 indicating a potential upside of 85.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $29.84, where the lowest estimate suggests a 33% increase to $50.00, and the highest estimate predicts a surge of 176.7% to $104.00 [2] - Analysts show strong agreement on XOMA's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for XOMA's current year earnings has risen by 45.5% over the past month, with no negative revisions [12] - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ: HLVX) ( ...

XOMA Corporation (NasdaqGM:XOMA) FY Conference September 08, 2025 09:00 AM ET Company ParticipantsBrad Sitko - CIOOwen Hughes - CEO & DirectorOperatorToday we have Owen Hughes, CEO, and Brad Sitko, Chief Investment Officer. The floor is yours.Owen HughesThank you very much, Josh. Really appreciate it. Thanks for coming this morning. I'm not a big fan of doing presentations. I think we can make this interactive by all means. Ask any questions. We'll give you an overview of where the company is, kind of what ...

Core Viewpoint - XOMA Royalty (XOMA) shares have increased by 22.2% in the past four weeks, closing at $34.76, with a potential upside of 86.1% based on Wall Street analysts' mean price target of $64.67 [1] Price Targets - The average price targets range from a low of $35.00 to a high of $104.00, with a standard deviation of $35.5, indicating variability among analysts [2] - The lowest estimate suggests a 0.7% increase from the current price, while the highest estimate indicates a potential upside of 199.2% [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about XOMA's earnings, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][9] - The Zacks Consensus Estimate for the current year has surged by 3671.4% over the past month, with three estimates revised upward and no negative revisions [10] Zacks Rank - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, and reliance solely on them may not yield satisfactory returns [5][8]

Core Viewpoint - XOMA Royalty Corporation will present a company update at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1][2]. Company Overview - XOMA Royalty Corporation is a biotechnology royalty aggregator that aids biotech companies in improving human health by acquiring potential future economics associated with therapeutic candidates licensed to pharmaceutical or biotechnology firms [3]. - The company provides non-dilutive, non-recourse funding to sellers, allowing them to advance their internal drug candidates or for general corporate purposes [3]. - XOMA Royalty has a growing portfolio of assets, defined as the rights to receive potential future economics linked to the advancement of underlying therapeutic candidates [3].

Core Viewpoint - XOMA Royalty (XOMA) has experienced a recent decline in share price, but the formation of a hammer chart pattern suggests a potential trend reversal due to increased buying interest and positive earnings outlook from analysts [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, where the stock opens lower, makes a new low, but then closes near its opening price, suggesting that selling pressure may be exhausting [4][5]. - This pattern is significant as it occurs during a downtrend, signaling that bears may be losing control and bulls are gaining strength [5]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for XOMA, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 3671.4% over the last 30 days, indicating strong agreement among analysts regarding improved earnings potential [8]. - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Mural Oncology plc has entered into a definitive agreement with XOMA Royalty Corporation for the acquisition of Mural's entire issued share capital, which is seen as beneficial for Mural shareholders following a strategic review process [1][52]. Transaction Details - The acquisition will provide Mural shareholders with a base cash price of $2.035 per share, with the potential for an additional cash amount of up to $0.205 per share based on Mural's Closing Net Cash exceeding estimated amounts [2][54]. - The total valuation of Mural's share capital in the acquisition is approximately $36.2 million, excluding any additional payments [4][56]. - The acquisition is expected to close by the end of 2025, subject to shareholder approval and High Court sanction [9][53]. Strategic Review Background - Mural Oncology is focused on developing cytokine-based immunotherapies for cancer treatment [13][63]. - Following unsuccessful clinical trials, Mural decided to explore strategic alternatives to maximize shareholder value, leading to the acquisition proposal from XOMA Royalty [14][64]. - The Mural Board evaluated various options, including liquidation and reverse takeovers, concluding that the acquisition was the best route for shareholder value [71][72]. Board Recommendations - The Mural Board, advised by Lucid Capital Markets, considers the acquisition terms fair and reasonable, recommending that shareholders vote in favor [8][73]. - Mural directors holding approximately 0.42% of shares have committed to vote in favor of the acquisition [7][74].

Group 1 - The proposed sale of HilleVax, Inc. to XOMA Royalty Corporation involves shareholders receiving $1.95 in cash per share, along with a non-transferable contingent value right for additional payments under certain conditions [1] - Kahn Swick & Foti, LLC is investigating whether the proposed consideration adequately reflects the value of HilleVax, indicating potential undervaluation [1] - The transaction is structured as a tender offer, emphasizing the importance of timely action for shareholders [3] Group 2 - Shareholders who believe the transaction undervalues HilleVax are encouraged to contact Kahn Swick & Foti for discussions regarding their legal rights [2] - Kahn Swick & Foti is led by former Louisiana Attorney General Charles C. Foti, Jr., highlighting the firm's legal expertise [3] - The investigation aims to ensure that the process leading to the proposed sale is fair and transparent for shareholders [1]

Group 1 - XOMA Royalty's shares have increased by 22.2% over the past four weeks, closing at $31.37, with a mean price target of $64.67 indicating a potential upside of 106.2% [1] - The average price targets range from a low of $35.00 to a high of $104.00, with a standard deviation of $35.5, suggesting variability in analysts' estimates [2] - Analysts show strong agreement on XOMA's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - The Zacks Consensus Estimate for XOMA's current year has increased by 1885.7%, with two estimates moving higher and no negative revisions [12] - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]